112 related articles for article (PubMed ID: 15887291)
21. Testicular Diffuse Large B-Cell Lymphoma-Clinical, Molecular, and Immunological Features.
Pollari M; Leivonen SK; Leppä S
Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439203
[TBL] [Abstract][Full Text] [Related]
22. The immune contexture of primary central nervous system diffuse large B cell lymphoma associates with patient survival and specific cell signaling.
Alame M; Cornillot E; Cacheux V; Rigau V; Costes-Martineau V; Lacheretz-Szablewski V; Colinge J
Theranostics; 2021; 11(8):3565-3579. PubMed ID: 33664848
[No Abstract] [Full Text] [Related]
23. Current Clinical Applications and Future Perspectives of Immune Checkpoint Inhibitors in Non-Hodgkin Lymphoma.
Apostolidis J; Sayyed A; Darweesh M; Kaloyannidis P; Al Hashmi H
J Immunol Res; 2020; 2020():9350272. PubMed ID: 33178841
[TBL] [Abstract][Full Text] [Related]
24. Clinical impact of combined epigenetic and molecular analysis of pediatric low-grade gliomas.
Fukuoka K; Mamatjan Y; Tatevossian R; Zapotocky M; Ryall S; Stucklin AG; Bennett J; Nobre LF; Arnoldo A; Luu B; Wen J; Zhu K; Leon A; Torti D; Pugh TJ; Hazrati LN; Laperriere N; Drake J; Rutka JT; Dirks P; Kulkarni AV; Taylor MD; Bartels U; Huang A; Zadeh G; Aldape K; Ramaswamy V; Bouffet E; Snuderl M; Ellison D; Hawkins C; Tabori U
Neuro Oncol; 2020 Oct; 22(10):1474-1483. PubMed ID: 32242226
[TBL] [Abstract][Full Text] [Related]
25. T-cell inflamed tumor microenvironment predicts favorable prognosis in primary testicular lymphoma.
Leivonen SK; Pollari M; Brück O; Pellinen T; Autio M; Karjalainen-Lindsberg ML; Mannisto S; Kellokumpu-Lehtinen PL; Kallioniemi O; Mustjoki S; Leppä S
Haematologica; 2019 Feb; 104(2):338-346. PubMed ID: 30237271
[TBL] [Abstract][Full Text] [Related]
26. HLA dependent immune escape mechanisms in B-cell lymphomas: Implications for immune checkpoint inhibitor therapy?
Nijland M; Veenstra RN; Visser L; Xu C; Kushekhar K; van Imhoff GW; Kluin PM; van den Berg A; Diepstra A
Oncoimmunology; 2017; 6(4):e1295202. PubMed ID: 28507804
[TBL] [Abstract][Full Text] [Related]
27. Proteomics Based Identification of Proteins with Deregulated Expression in B Cell Lymphomas.
Wu R; Nijland M; Rutgers B; Veenstra R; Langendonk M; van der Meeren LE; Kluin PM; Li G; Diepstra A; Chiu JF; van den Berg A; Visser L
PLoS One; 2016; 11(1):e0146624. PubMed ID: 26752561
[TBL] [Abstract][Full Text] [Related]
28. Genome-wide association study identifies shared risk loci common to two malignancies in golden retrievers.
Tonomura N; Elvers I; Thomas R; Megquier K; Turner-Maier J; Howald C; Sarver AL; Swofford R; Frantz AM; Ito D; Mauceli E; Arendt M; Noh HJ; Koltookian M; Biagi T; Fryc S; Williams C; Avery AC; Kim JH; Barber L; Burgess K; Lander ES; Karlsson EK; Azuma C; Modiano JF; Breen M; Lindblad-Toh K
PLoS Genet; 2015 Feb; 11(2):e1004922. PubMed ID: 25642983
[TBL] [Abstract][Full Text] [Related]
29. Immunomodulatory effects of hemagglutinin- (HA-) modified A20 B-cell lymphoma expanded as a brain tumor on adoptively transferred HA-Specific CD4+ T cells.
Shichkin VP; Moriev RM
ScientificWorldJournal; 2014; 2014():165265. PubMed ID: 24693228
[TBL] [Abstract][Full Text] [Related]
30. Influence of Tumor Location on the Composition of Immune Infiltrate and Its Impact on Patient Survival. Lessons from DCBCL and Animal Models.
Galand C; Donnou S; Molina TJ; Fridman WH; Fisson S; Sautès-Fridman C
Front Immunol; 2012; 3():98. PubMed ID: 22566974
[TBL] [Abstract][Full Text] [Related]
31. Insights into the biology of primary central nervous system lymphoma.
Mrugala MM; Rubenstein JL; Ponzoni M; Batchelor TT
Curr Oncol Rep; 2009 Jan; 11(1):73-80. PubMed ID: 19080745
[TBL] [Abstract][Full Text] [Related]
32. Tumor immunoediting and immunosculpting pathways to cancer progression.
Reiman JM; Kmieciak M; Manjili MH; Knutson KL
Semin Cancer Biol; 2007 Aug; 17(4):275-87. PubMed ID: 17662614
[TBL] [Abstract][Full Text] [Related]
33. Control of T-cell-mediated immune response by HLA class I in human pancreatic carcinoma.
Ryschich E; Nötzel T; Hinz U; Autschbach F; Ferguson J; Simon I; Weitz J; Fröhlich B; Klar E; Büchler MW; Schmidt J
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):498-504. PubMed ID: 15701833
[TBL] [Abstract][Full Text] [Related]
34. Hemizygous deletions in the HLA region account for loss of heterozygosity in the majority of diffuse large B-cell lymphomas of the testis and the central nervous system.
Jordanova ES; Riemersma SA; Philippo K; Giphart-Gassler M; Schuuring E; Kluin PM
Genes Chromosomes Cancer; 2002 Sep; 35(1):38-48. PubMed ID: 12203788
[TBL] [Abstract][Full Text] [Related]
35. HLA-G expression in malignant melanoma.
Rebmann V; Wagner S; Grosse-Wilde H
Semin Cancer Biol; 2007 Dec; 17(6):422-9. PubMed ID: 17689098
[TBL] [Abstract][Full Text] [Related]
36. Cytotoxic T lymphocyte therapy of cancer and tumor escape mechanisms.
Melief CJ; Kast WM
Semin Cancer Biol; 1991 Oct; 2(5):347-54. PubMed ID: 1773050
[TBL] [Abstract][Full Text] [Related]
37. High numbers of tumour-infiltrating activated cytotoxic T lymphocytes, and frequent loss of HLA class I and II expression, are features of aggressive B cell lymphomas of the brain and testis.
Riemersma SA; Oudejans JJ; Vonk MJ; Dreef EJ; Prins FA; Jansen PM; Vermeer MH; Blok P; Kibbelaar RE; Muris JJ; Schuuring EM; Kluin PM
J Pathol; 2005 Jul; 206(3):328-36. PubMed ID: 15887291
[TBL] [Abstract][Full Text] [Related]
38. Mechanisms and effects of loss of human leukocyte antigen class II expression in immune-privileged site-associated B-cell lymphoma.
Booman M; Douwes J; Glas AM; Riemersma SA; Jordanova ES; Kok K; Rosenwald A; de Jong D; Schuuring E; Kluin PM
Clin Cancer Res; 2006 May; 12(9):2698-705. PubMed ID: 16675561
[TBL] [Abstract][Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
